In ET, most patients harbor a mutation in one of three genes: JAK2 V617F (in 60%), CALR (in 20%), or MPL in (3%), with the distribution of type 1 and type 2 mutations being similar (51 vs. 39% of pts, respectively) [14–16]. Here, CALR is linked to essential thrombocythemia.